Sivik Global Healthcare LLC Purchases 6,500 Shares of Insulet Co. (NASDAQ:PODD)

Sivik Global Healthcare LLC lifted its position in Insulet Co. (NASDAQ:PODD) by 32.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,500 shares of the medical instruments supplier’s stock after acquiring an additional 6,500 shares during the quarter. Insulet accounts for approximately 2.4% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 23rd largest holding. Sivik Global Healthcare LLC’s holdings in Insulet were worth $5,750,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in PODD. Parkside Financial Bank & Trust increased its holdings in shares of Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 123 shares during the period. Allworth Financial LP lifted its position in shares of Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 92 shares during the last quarter. Wolff Wiese Magana LLC boosted its holdings in shares of Insulet by 2,680.0% in the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 134 shares in the last quarter. BluePath Capital Management LLC bought a new stake in shares of Insulet in the 3rd quarter valued at about $31,000. Finally, Lindbrook Capital LLC grew its position in shares of Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 75 shares during the last quarter.

Insulet Stock Performance

Shares of Insulet stock traded up $1.68 during trading on Tuesday, hitting $171.94. 758,586 shares of the company’s stock were exchanged, compared to its average volume of 857,969. The stock has a market capitalization of $12.04 billion, a price-to-earnings ratio of 59.09, a PEG ratio of 2.99 and a beta of 0.98. The business has a 50-day simple moving average of $171.09 and a 200-day simple moving average of $180.25. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The business had revenue of $509.80 million during the quarter, compared to analyst estimates of $461.26 million. During the same quarter last year, the business posted $0.55 EPS. The company’s revenue was up 37.9% on a year-over-year basis. On average, research analysts forecast that Insulet Co. will post 3.08 EPS for the current year.

Insider Buying and Selling at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares of the company’s stock, valued at $418,215.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.47% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on PODD shares. Stifel Nicolaus raised their target price on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a research note on Monday, February 5th. Piper Sandler lowered their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Barclays reduced their target price on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. boosted their price target on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $243.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.